Internal Reference Number: FOI_8687
Date Request Received: 03/06/2025 00:00:00
Date Request Replied To: 26/06/2025 00:00:00
This response was sent via: By Email
Request Summary: Oncology Breast Cancer
Request Category: Researcher
| Question Number 1: I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following questions How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Alpelisib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel • Atezolizumab • Capivasertib • Capecitabine as a single agent • Carboplatin + Paclitaxel • Elacestrant • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fulvestrant as a single agent • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Palbociclib + Fulvestrant • Parp Inhibitors (Olaparib/Talazoparib) • Pembrolizumab Monotherapy • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Pembrolizumab • Carboplatin + Paclitaxel + Pembrolizumab • Pertuzumab (Perteja) + Trastuzumab (Herceptin) • Phesgo (Pertuzumab + Trastuzumab in a single injection) • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Ribociclib + Fulvestrant • Sacituzumab Govitecan • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Trastuzumab deruxtecan (Enhertu) • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel • Trastuzumab emtansine (Kadcyla) • Any other active systemic anti-cancer therapy • Aromatase Inhibitor as a single agent | |
| Answer To Question 1: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) - 30 • Abemaciclib + Fulvestrant - 6 • Alpelisib + Fulvestrant - <5 • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide - <5 • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel - 0 • Atezolizumab - 0 • Capivasertib - <5 • Capecitabine as a single agent - 10 • Carboplatin + Paclitaxel - <5 • Elacestrant - <5 • Eribulin as a single agent or in combination - <5 • Everolimus + Exemestane - <5 • Fulvestrant as a single agent - 0 • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) - 25 • Palbociclib + Fulvestrant - <5 • Parp Inhibitors (Olaparib/Talazoparib) - 0 • Pembrolizumab Monotherapy - <5 • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Pembrolizumab - <5 • Carboplatin + Paclitaxel + Pembrolizumab - 0 • Pertuzumab (Perteja) + Trastuzumab (Herceptin) - <5 • Phesgo (Pertuzumab + Trastuzumab in a single injection) - 21 • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) - 17 • Ribociclib + Fulvestrant - <5 • Sacituzumab Govitecan - 7 • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent - <5 • Trastuzumab deruxtecan (Enhertu) - 5 • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel - 11 • Trastuzumab emtansine (Kadcyla) - <5 • Any other active systemic anti-cancer therapy - 13 • Aromatase Inhibitor as a single agent - can’t answer as single agent not prescribed on Aria and patients would get from the GP. | |
| Question Number 2: How many patients have been treated for metastatic breast cancer in the past 3 months with the following systemic anti-cancer therapies: • Phesgo (Pertuzumab + Trastuzumab in a single injection) • Pertuzumab (Perteja) + Trastuzumab (Herceptin) • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel • Trastuzumab deruxtecan (Enhertu) • Trastuzumab emtansine (Kadcyla) • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Ribociclib + Fulvestrant • Capecitabine as a single agent • Carboplatin + Paclitaxel • Carboplatin + Paclitaxel + Pembrolizumab | |
| Answer To Question 2: • Phesgo (Pertuzumab + Trastuzumab in a single injection) - 12 • Pertuzumab (Perteja) + Trastuzumab (Herceptin) - <5 • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel - 5 • Trastuzumab deruxtecan (Enhertu) - 5 • Trastuzumab emtansine (Kadcyla) - 0 • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) - 6 • Abemaciclib + Fulvestrant - 6 • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) - 16 • Ribociclib + Fulvestrant - <5 • Capecitabine as a single agent - 11 • Carboplatin + Paclitaxel - 0 • Carboplatin + Paclitaxel + Pembrolizumab - 0 | |
| Question Number 3: Does your trust participate in any Clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part. | |
| Answer To Question 3: The answers to Q3 are in the attached document. To accompany this answer to question 3 please also see the documents listed below:  FOI 8687 - Q3.pdf | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
